HOUSTON, March 3, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the results from its pivotal cellulite trial have been
accepted for oral presentation at the American Academy of
Dermatology (AAD) 2020 Annual Meeting, being held March 20-24 in Denver,
CO.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
"We are thrilled that our pivotal cellulite data has been
accepted for podium presentation by a member of Soliton's
Scientific Advisory Board and leading dermatologist, Dr.
Elizabeth Tanzi, during one of the
most prestigious dermatology conferences," stated Christopher Capelli, MD, founder, President and
CEO of Soliton. "Globally, cellulite affects between 80-90% of
women and there is approximately $2.4
billion per year spent on treatment, making it an attractive
market for our RAP device. We believe our RAP device is
uniquely capable of selective disruption of the fibrotic septa that
contribute to the appearance of cellulite, called acoustic
subcision. We look forward to sharing the pivotal results
regarding the potential of the RAP device to be a solution to
improve the unwanted appearance of cellulite."
Details of the presentation include:
Don't Neglect the Body! Non-facial Laser Skin
Rejuvenation
- Session: S034 – Dermatologic Surgery: Cosmetic Tips and
Pearls
- Presenter: Dr. Elizabeth Tanzi,
Director at Capital Laser & Skin Care, Chevy Chase, MD
- Date and time: Saturday, March
21st 3:15 – 3:26 p.m.
MT
- Location: Room 405
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
cellulite and the ability for Soliton to receive FDA clearance for
this additional indication. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-to-present-pivotal-cellulite-clinical-trial-results-at-aad-on-march-21-2020-301015019.html
SOURCE Soliton, Inc.